Graham Abra, MD
Nephrology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: 052793 · 052891 · 552756 · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Abra’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A102026 · Current
Licensed to practise in California · since 2007 · expires 2027-08-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$128,057
Medicare paid this office $128,057 for 308 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 109 | $20,766 | $70 |
| Long return visit (40+ min) | 55 | $14,678 | $169 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 16 | $14,193 | $268 |
| Long return visit (40+ min) | 51 | $12,837 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $7,326 | $153 |
See all 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 109 | $20,766 | $70 |
| Long return visit (40+ min) | 55 | $14,678 | $169 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 16 | $14,193 | $268 |
| Long return visit (40+ min) | 51 | $12,837 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $7,326 | $153 |
| Return visit (30+ min) | 46 | $5,942 | $106 |
| Critical care, first 30-74 minutes | 13 | $5,634 | $182 |
| New patient visit (60+ min) | 30 | $4,566 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,148 | $106 |
| Return visit (30+ min) | 38 | $3,775 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,758 | $110 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,280 | $116 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 59 | $1,138 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 51 | $1,094 | $15 |
Who their Medicare patients are
308 Original Medicare patients in 2024. Average age 71 · Under 65 20% · 85 and older 13% · Women 50% · Also on Medicaid 45% · Health risk score 4.93. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 62% · Heart failure 49% · Coronary heart disease 48% · Atrial fibrillation 37% · Depression 24% · Cancer 21% · COPD 21% · Stroke 21% · Dementia 19%.
The office billed $576,555, Medicare allowed $165,068 and paid $128,057; for 1,207 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 308 | 1,207 | 71 | 4.93 | $576,555 | $128,057 |
| 2023 | 200 | 583 | 72 | 4.85 | $257,982 | $62,202 |
| 2022 | 185 | 452 | 71 | 4.15 | $220,295 | $49,456 |
| 2021 | 176 | 549 | 69 | 4.39 | $317,876 | $74,626 |
| 2020 | 173 | 671 | 69 | 4.14 | $347,585 | $74,813 |
| 2019 | 183 | 690 | 68 | 4.77 | $275,822 | $68,881 |
| 2018 | 156 | 542 | 67 | 5.29 | $196,465 | $52,781 |
| 2017 | 151 | 480 | 67 | 4.98 | $155,457 | $43,926 |
| 2016 | 177 | 505 | 65 | 5.24 | $165,547 | $45,730 |
| 2015 | 76 | 136 | 67 | 4.26 | $46,526 | $13,538 |
| 2014 | 22 | 46 | 68 | 6.34 | $12,391 | $3,737 |
| 2013 | 38 | 74 | 75 | 5.98 | $19,164 | $5,279 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 66 | $10,323 | $87 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $9,671 | $269 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 53 | $8,899 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,391 | $161 |
| New patient visit (60+ min) | 24 | $3,173 | $132 |
| Short return visit (20+ min) | 41 | $2,261 | $48 |
2022: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $9,158 | $65 |
| Return visit (30+ min) | 45 | $6,001 | $80 |
| New patient visit (60+ min) | 26 | $3,322 | $128 |
| Short return visit (20+ min) | 38 | $3,265 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,751 | $183 |
2021: 6 services
| Home dialysis services per month (20 years or older) | 12 | $23,078 | $272 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $9,663 | $65 |
| Return visit (30+ min) | 36 | $6,317 | $84 |
| Short return visit (20+ min) | 49 | $5,413 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,516 | $185 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,616 | $70 |
2020: 9 services
| Dialysis services, 2-3 physician visits per month (20 years or older) | 15 | $12,990 | $220 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $10,492 | $67 |
| Dialysis services, 1 physician visit per month (20 years or older) | 12 | $6,054 | $159 |
| New patient visit (60+ min) | 22 | $3,352 | $152 |
| Return visit (30+ min) | 33 | $3,321 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,000 | $187 |
| Short return visit (20+ min) | 33 | $2,187 | $41 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,476 | $74 |
| Short return visit (20+ min) | 11 | $570 | $47 |
2019: 9 services
| Home dialysis services per month (20 years or older) | 15 | $15,915 | $212 |
| Dialysis services, 1 physician visit per month (20 years or older) | 19 | $12,973 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $11,943 | $66 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $7,685 | $213 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,238 | $183 |
| Short return visit (20+ min) | 68 | $5,049 | $41 |
| New patient visit (60+ min) | 19 | $2,672 | $141 |
| Long return visit (40+ min) | 17 | $1,918 | $101 |
| Return visit (30+ min) | 11 | $933 | $72 |
2018: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $12,484 | $65 |
| Dialysis services, 1 physician visit per month (20 years or older) | 13 | $8,685 | $167 |
| Short return visit (20+ min) | 59 | $6,378 | $42 |
| New patient visit (60+ min) | 14 | $1,964 | $140 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,833 | $122 |
2017: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 60 | $10,235 | $65 |
| Short return visit (20+ min) | 49 | $5,431 | $43 |
| Dialysis services, 1 physician visit per month (20 years or older) | 13 | $4,772 | $159 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,417 | $122 |
| New patient visit (60+ min) | 17 | $2,555 | $150 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 74 | $12,336 | $64 |
| Short return visit (20+ min) | 58 | $5,368 | $41 |
| New patient visit (60+ min) | 34 | $4,815 | $142 |
| Dialysis services, 1 physician visit per month (20 years or older) | 14 | $3,996 | $167 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,794 | $120 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,249 | $83 |
2015: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,173 | $66 |
| New patient visit (60+ min) | 16 | $2,404 | $150 |
| Short return visit (20+ min) | 19 | $958 | $46 |
2014: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,306 | $64 |
2013: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,591 | $59 |
Medicaid work
$5,509 in 2024
Medicaid paid $5,509 for 241 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 214 | $4,001 |
| Long return visit (40+ min) | 27 | $1,508 |
| 2024 | 241 | 2 | 16 | $5,509 |
| 2023 | 183 | 3 | 21 | $6,167 |
| 2022 | 33 | 1 | 12 | $803 |
| 2021 | 67 | 1 | 15 | $1,664 |
| 2020 | 55 | 1 | 16 | $1,926 |
| 2019 | 90 | 1 | 21 | $2,912 |
| 2018 | 95 | 1 | 15 | $2,927 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 118 | $2,929 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 12 | $2,017 |
| Return visit (30+ min) | 53 | $1,220 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 33 | $803 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 67 | $1,664 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 55 | $1,926 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 90 | $2,912 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 95 | $2,927 |
Drugs they prescribed that Part D paid
$316,025
Pharmacies billed $316,025 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (12 of 989) in 2024. A higher opioid share than 9 in 10 peers; the typical nephrology clinician is at 0%.
716 generic and 273 brand-name prescriptions · $316,025 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Farxiga | 64 | $84,695 | $1,323 |
| Jardiance | 45 | $52,652 | $1,170 |
| Ozempic | 29 | $40,966 | $1,413 |
| Kerendia | 20 | $19,143 | $957 |
| Veltassa | 12 | $14,770 | $1,231 |
See all 30 drugs
| Farxiga | 64 | $84,695 | $1,323 |
| Jardiance | 45 | $52,652 | $1,170 |
| Ozempic | 29 | $40,966 | $1,413 |
| Kerendia | 20 | $19,143 | $957 |
| Veltassa | 12 | $14,770 | $1,231 |
| Mounjaro | 12 | $11,717 | $976 |
| Renvela | 11 | $10,450 | $950 |
| Sevelamer Carbonate | 22 | $6,426 | $292 |
| Procrit | 12 | $6,319 | $527 |
| Calcium Acetate | 23 | $2,318 | $101 |
| Eplerenone | 16 | $1,282 | $80 |
| Atorvastatin | 63 | $596 | $9 |
| Chlorthalidone | 41 | $576 | $14 |
| Furosemide | 51 | $555 | $11 |
| Torsemide | 17 | $553 | $33 |
| Losartan | 84 | $536 | $6 |
| Gabapentin | 21 | $490 | $23 |
| Carvedilol | 45 | $434 | $10 |
| Tamsulosin | 18 | $329 | $18 |
| Olmesartan Medoxomil | 18 | $311 | $17 |
| Calcitriol | 18 | $292 | $16 |
| Spironolactone | 17 | $233 | $14 |
| Rosuvastatin | 18 | $228 | $13 |
| Amlodipine Besylate | 53 | $189 | $4 |
| Acetaminophen-Codeine | 12 | $176 | $15 |
| Hydrochlorothiazide | 13 | $120 | $9 |
| Lisinopril | 18 | $86 | $5 |
| Levothyroxine | 11 | $58 | $5 |
| Alprazolam | 11 | $42 | $4 |
| Paroxetine | 13 | $24 | $2 |
Year by year
| 2024 | 989 | 138 | 1% (12) | 28% | $316,025 |
| 2023 | 522 | 86 | 3% (18) | None | $185,985 |
| 2022 | 550 | 68 | None | 20% | $147,924 |
| 2021 | 586 | 73 | 2% (11) | 17% | $133,639 |
| 2020 | 490 | 69 | None | 17% | $110,472 |
| 2019 | 440 | 71 | None | 15% | $79,694 |
| 2018 | 374 | 58 | 0% (0) | 19% | $75,812 |
| 2017 | 346 | 45 | 0% (0) | None | $106,428 |
| 2016 | 232 | 40 | 0% (0) | 24% | $49,472 |
| 2015 | 19 | None | 0% (0) | None | $6,351 |
| 2014 | 11 | None | None | None | $321 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Farxiga | 44 | $67,969 | $1,545 |
| Jardiance | 27 | $20,555 | $761 |
| Tradjenta | 12 | $6,621 | $552 |
| Rosuvastatin | 20 | $1,930 | $96 |
| Losartan | 30 | $772 | $26 |
| Torsemide | 11 | $648 | $59 |
| Chlorthalidone | 30 | $557 | $19 |
| Furosemide | 23 | $394 | $17 |
| Amlodipine Besylate | 30 | $325 | $11 |
| Atorvastatin | 18 | $316 | $18 |
| Calcitriol | 12 | $279 | $23 |
| Acetaminophen-Codeine | 11 | $184 | $17 |
| Allopurinol | 11 | $175 | $16 |
| Carvedilol | 21 | $174 | $8 |
| Lisinopril | 17 | $132 | $8 |
2022: 17 drugs
| Farxiga | 31 | $35,106 | $1,132 |
| Jardiance | 14 | $13,171 | $941 |
| Tradjenta | 13 | $6,754 | $520 |
| Edarbyclor | 11 | $2,430 | $221 |
| Rosuvastatin | 19 | $1,535 | $81 |
| Chlorthalidone | 42 | $638 | $15 |
| Losartan | 38 | $563 | $15 |
| Hydralazine | 12 | $425 | $35 |
| Torsemide | 16 | $333 | $21 |
| Carvedilol | 24 | $306 | $13 |
| Tamsulosin | 13 | $283 | $22 |
| Amlodipine Besylate | 30 | $227 | $8 |
| Allopurinol | 25 | $210 | $8 |
| Furosemide | 20 | $194 | $10 |
| Metoprolol | 20 | $165 | $8 |
| Doxazosin Mesylate | 12 | $164 | $14 |
| Atorvastatin | 13 | $132 | $10 |
2021: 17 drugs
| Invokana | 16 | $25,652 | $1,603 |
| Farxiga | 29 | $23,553 | $812 |
| Clinisol | 55 | $7,711 | $140 |
| Sevelamer Carbonate | 12 | $5,624 | $469 |
| Chlorthalidone | 28 | $710 | $25 |
| Acetaminophen-Codeine | 11 | $387 | $35 |
| Carvedilol | 27 | $352 | $13 |
| Tamsulosin | 27 | $342 | $13 |
| Allopurinol | 24 | $308 | $13 |
| Torsemide | 13 | $248 | $19 |
| Amlodipine Besylate | 36 | $234 | $7 |
| Losartan | 30 | $225 | $8 |
| Furosemide | 19 | $179 | $9 |
| Doxazosin Mesylate | 12 | $150 | $13 |
| Gabapentin | 12 | $146 | $12 |
| Atorvastatin | 17 | $130 | $8 |
| Lisinopril | 19 | $60 | $3 |
2020: 14 drugs
| Cinacalcet | 16 | $24,467 | $1,529 |
| Auryxia | 11 | $12,453 | $1,132 |
| Clinisol | 50 | $7,890 | $158 |
| Chlorthalidone | 14 | $588 | $42 |
| Losartan | 30 | $382 | $13 |
| Torsemide | 17 | $370 | $22 |
| Doxazosin Mesylate | 12 | $338 | $28 |
| Furosemide | 25 | $308 | $12 |
| Levothyroxine | 11 | $299 | $27 |
| Amlodipine Besylate | 32 | $270 | $8 |
| Allopurinol | 20 | $252 | $13 |
| Gabapentin | 15 | $211 | $14 |
| Carvedilol | 17 | $203 | $12 |
| Tamsulosin | 12 | $151 | $13 |
2019: 12 drugs
| Cinacalcet | 15 | $26,826 | $1,788 |
| Clinisol | 25 | $2,594 | $104 |
| Calcium Acetate | 23 | $949 | $41 |
| Torsemide | 24 | $733 | $31 |
| Doxazosin Mesylate | 15 | $416 | $28 |
| Amlodipine Besylate | 40 | $346 | $9 |
| Tamsulosin | 14 | $265 | $19 |
| Losartan | 26 | $245 | $9 |
| Gabapentin | 13 | $236 | $18 |
| Allopurinol | 13 | $179 | $14 |
| Furosemide | 23 | $170 | $7 |
| Zolpidem | 12 | $165 | $14 |
2018: 9 drugs
| Renvela | 11 | $30,840 | $2,804 |
| Doxazosin Mesylate | 27 | $826 | $31 |
| Torsemide | 19 | $671 | $35 |
| Amlodipine Besylate | 44 | $444 | $10 |
| Levothyroxine | 15 | $356 | $24 |
| Losartan | 26 | $270 | $10 |
| Allopurinol | 13 | $255 | $20 |
| Furosemide | 13 | $168 | $13 |
| Lisinopril | 12 | $67 | $6 |
2017: 8 drugs
| Sensipar | 30 | $52,701 | $1,757 |
| Renvela | 21 | $28,656 | $1,365 |
| Calcium Acetate | 13 | $1,728 | $133 |
| Furosemide | 45 | $490 | $11 |
| Doxazosin Mesylate | 19 | $446 | $23 |
| Amlodipine Besylate | 25 | $171 | $7 |
| Losartan | 24 | $142 | $6 |
| Carvedilol | 11 | $103 | $9 |
2016: 6 drugs
| Sensipar | 15 | $21,685 | $1,446 |
| Renvela | 11 | $15,851 | $1,441 |
| Clinisol | 19 | $1,994 | $105 |
| Furosemide | 24 | $248 | $10 |
| Losartan | 22 | $190 | $9 |
| Carvedilol | 14 | $106 | $8 |
Money from drug and device companies
$100 in 2025
| 2025 | 1 | 1 | None | $100 |
| 2024 | 4 | 12 | $3,750 | $5,602 |
| 2023 | 3 | 5 | $3,698 | $4,019 |
| 2022 | 2 | 7 | None | $2,371 |
| 2021 | 1 | 1 | $2,040 | $2,040 |
| 2020 | 1 | 1 | $4,000 | $4,000 |
| 2019 | 2 | 2 | None | $38 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| NxStage Medical | Liberty Select Cycler | $100 | 1 payment
|
See the published payment
| NxStage Medical | Meals · 2025-08-28 | Liberty Select Cycler | $100 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $5,602
| Fresenius USA Marketing | None | $5,264 | 9 payments
|
| Nxstage Medical | Liberty Select Cycler | $190 | 1 payment
|
| Otsuka America Pharmaceutical | None | $145 | 1 payment
|
| Travere Therapeutics | None | $3 | 1 payment
|
2023: $4,019
| Baxter Healthcare | Renal - Pd | $3,871 | 2 payments
|
| NxStage Medical | Liberty Select Cycler | $122 | 2 payments
|
| Outset Medical | None | $26 | 1 payment
|
2022: $2,371
| Outset Medical | None | $1,998 | 3 payments
|
| Baxter Healthcare | Renal - Pd | $373 | 4 payments
|
2021: $2,040
| Akebia Therapeutics | None | $2,040 | 1 payment
|
2020: $4,000
| Akebia Therapeutics | None | $4,000 | 1 payment
|
2019: $38
| AstraZeneca Pharmaceuticals LP | Lokelma | $20 | 1 payment
|
| Amgen | None | $18 | 1 payment
|
Professional record
- NPI
- 1760644678
- Licence
- CA A102026California A102026: Current · expires 2027-08-31
- Trained
- University of California, San Diego School of Medicine, 2006
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-07-01
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1804 Embarcadero Rd, Palo Ato, CA, 94303 · 200 W Arbor Dr, San Diego, CA, 92103